Spore.bio

Manufacturers from a variety of industries, such as food, pharmaceuticals, and cosmetics, have had a long history of dealing with slow, ineffective microbiological testing. The typical lab-based techniques can take anywhere from several hours to days to detect the presence of pathogens, which creates immense safety and quality control issues. As the industry continues to pivot toward the real-time biosafety tools, an emerging group of casters is step up, and Spore.bio is the first company out the gate. 

Spore.bio is transforming the world of industrial microbiology with their AI-powered, real-time bacteria detection platform. CEO Amine Raji's team has developed a smart, real-time diagnostic device for industrial, on-site diagnostic testing. The device detects harmful bacteria using light-based spectroscopy and deep learning, which only takes minutes. Their smart portable device designed for the factory floor joins a cloud-based analytics suite to provide actionable real-time insights about hygiene. Their mission is to speed up, enhance, and simplify an incredibly slow and lab-based field. If operators load a sample into the device, the detection system will generate a unique optical signature of the microbes. Then, Spore.bio's trained AI models will detect, identify, and quantify — which normally takes a lab anywhere from 3 to 5 days — and allow manufacturers to transition from testing reactively to preventing contamination.

Spore.bio does not simply stop at detection. The company provides a fully integrated hygiene intelligence platform consisting of predictive analytics, anomaly detection, and process optimization tools. Through its collaborations with one of the world’s leading microbiology institutions, the Institut Pasteur, the firm has access to more than 30,000 unique strains of bacteria—the largest dataset in the world of its type—allowing their AI model to obtain unparalleled detection accuracy. The other startup they acquired in 2024, Greentropism, is a fellow spectral-analysis startup and allowed Spore.bio further to shore up its IP-farm of cutting edge technology and extended the company’s competitive advantage. These partnerships and acquisitions have also allowed the company to usher in further R&D and onboard new clients in some of the more highly regulated sectors.

Spore.bio offers a tiered service model combining hardware sales, with a monthly SaaS subscription model, resulting in recurring revenue streams while paving cornerstone technologies for our clients that reduce their upfront costs.  Service types vary from rapid on-site testing to enterprise-wide hygiene mapping and reporting tools for regulatory compliance. The firm has a commercial deployment pipeline for over 200 manufacturing plants already. With high demand, the company has initiated a waitlist system. Currently, the company's operations are primarily focused in Europe. Nevertheless, it is already proceeding with international expansion. The company entered the United States of America in 2025 and Texas with teams in New York, San Francisco, and Chicago, with plans to pilot programs in Canada and Southeast Asia in early 2026 and the momentum for international expansion is well underway. By mid-2025, Spore.bio has increased its headcount to over 50 employees, more than doubling its headcount since one year ago.  The company's growth plan involves attracting world-class personnel in AI, biotech, and enterprise sales — mainly in France and the U.S. in support of the aggressive scale-up plan. The company's headcount growth of >100% over one year has, in conjunction, been achieved alongside upwards production capacity and strengthened client support infrastructure to manage clients with larger footprints and more frequent use cases.

In terms of funding, Spore.bio is one of the better funded startups we encountered in the industrial health-tech space, having closed a €22 million (~$24 million) Series A in February 2025 led by Singular, with follow-on contributions from Point72 Ventures, LocalGlobe, 1st Kind Ventures, Famille C., and existing investor HCVC. Prior to this, it had raised a €7.9 million (~$8.5 million) pre-seed round in late 2023, for a total of just over €30 million (~$33 million) in funding. Putting Spore.bio's estimated valuation around €120 million (~$130 million) as of mid-2025, it is one of the more valuable early-stage DeepTech startups in Europe. Based on a growing number of SaaS subscribers and device deployments, Sporebio's projected revenues for 2025 are more than €5 million (~$5.4 million). Although the venture is at early stages of commercialisation, feedback from people close to the company and its financials has indicated gross margins potentially above 60%, with its net losses markedly reduced in recent quarters. The company expects to achieve profitability by mid-2026 with long-term, contracted residuals and lower costs with scale of hardware production.

Competition is ramping up in the microbiological testing space. Here, Spore.bio is facing competitors from a variety of fronts, from legacy customer giants to new start-ups utilizing AI to drive diagnostics. While legacy players like bioMérieux, 3M (Clean-Trace), and Hygiena, typically in terms of total volume (especially in high-capex industrial environments), do a very good job, their traditional system will typically utilize consumables, workflows that are often manual, and microbiology expertise in the lab, which typically makes them slower and pricier for routine testing. There are also a number of new players such as Pathotrak and MicrosensDx in the space that are pushing for faster lab free diagnostics, yet many are still in the pilot phase, or do not currently have similar end-to-end analytics as offered by Spore.bio. While the firm is unique in that we do have the hybrid offering of AI speed, a simple user-based interface, and deep microbial datasets provided to us by our academic partners, we are fairly unique in the microbiological testing space. The company’s devices are ready to go, they are factory-friendly and do not require a microbiologist; results display in real-time, and automatically, and report back to users via the cloud dashboard. The firm has a hidden fee free and predictable brutal subscription price model, and you can’t turn off AI updates, which prevents users to forget usage - thus making our system scaleable and sticky.

Spore.bio has an exciting roadmap ahead that includes growing its capabilities to detect allergens, yeasts, or other microbiological threats, as well as application into ERP software and other quality control habitat models, to provide even more value as a full stack hygiene intelligence supplier. The company has its sights set on global growth with the United States, Canada, and Southeast Asia at the top of the list as attractive markets. 

CEO Amine Raji defines the company’s vision perfectly: “Spore.bio is here to change the microbiology scientific landscape as a reactive, lab science to a proactive, factory science.” With sound financials, cutting-edge technology, and strategic partnerships, Spore.bio is in a position to change how industrial hygiene is managed around the world. With a rapidly growing customer base, over €30 million in funding to date, the company operates in Europe and North America, and has grown to be over 50 employees, Spore.bio is not just an innovative health-tech firm; it is a future category king, well on its way to profitability and prominence in the AI diagnostic space.

Click here to access Spore.bio's website.